Altered thiol and calcium homeostasis in oxidative hepatocellular injury
Giorgio Bellomo, Sten Orrenius – 1 September 1985
Polycythemia and the budd‐chiari syndrome: Study of serum erythropoietin and bone marrow erythroid progenitors
Victor Georges Levy, Agnès Ruskone, Claude Baillou, Diana Thierman‐Duffaud, Albert Najman, Georges Albert Boffa – 1 September 1985 – The mechanism of polycythemia associated with the Budd‐Chiari syndrome is unknown. Erythropoiesis in 10 patients with Budd‐Chiari syndrome was studied in an attempt to distinguish prior unrecognized polycythemia vera from secondary polycythemia.
Diagnostic value of different antiliver/kidney microsome antibodies
M. Rizzetto, O. Crivelli, C. Andre, N. Abuaf, J. C. Homberg, Hyman J. Zimmerman – 1 September 1985
The liver and biliary system. Edited by P. W. Brunt, M. S. Losowsky and A. E. Read. London: William Heinemann Medical Books, Ltd., 1984.£7.95
Charles S. Davidson, Wade Volwiler – 1 September 1985
Acetaminophen hepatotoxicity and targeted rescue: A model for specific chemotherapy of hepatocellular carcinoma
George Y. Wu, Catherine H. Wu, Mark I. Rubin – 1 September 1985 – We have taken advantage of the presence of hepatic receptors for galactose‐terminal (asialo‐)glycoproteins to achieve targeted rescue of differentiated hepatocytes from acetaminophen‐induced toxicity in vitro. To accomplish this, a conjugate was formed by covalent coupling of N‐acetylcysteine (an acetaminophen antagonist) to galactose‐terminal (asialo‐)fetuin.
Program for the postgraduate course
1 September 1985
Transferrin and the alcoholic liver
Philip Aisen – 1 September 1985
Prognostic value of serum fibronectin concentration in alcoholic cirrhotic patients
Sylvie Naveau, Thierry Poynard, Annie Abella, Jean‐Pierre Pignon, Alain Poitrine, Hélène Agostini, Othar Zourabichvili, Jean‐Claude Chaput – 1 September 1985 – The aim of this study was to assess prospectively the prognostic value of serum fibronectin in 114 alcoholic cirrhotic patients and to compare serum fibronectin with other prognostic variables. The Cox model and log‐rank test were used to compare survival rates at 1 year.
Changes of hepatitis B virus DNA in liver and serum caused by recombinant leukocyte interferon treatment: Analysis of intrahepatic replicative hepatitis B virus DNA
Osamu Yokosuka, Masao Omata, Fumio Imazeki, Kunio Okuda, Jesse Summers – 1 September 1985 – Twenty patients with HBeAg‐positive chronic liver disease were given large doses of recombinant leukocyte interferon for 4 weeks. Changes of hepatitis B virus DNA in livers and sera were analyzed by the molecular hybridization technique in paired biopsies obtained before and 2 weeks after treatment. Serum hepatitis B virus DNA was examined before, during and after the treatment until 4 weeks post‐interferon.